LivingGLP1
Study S002372

Effect of Glucagon-like Peptide-1 Stimulation on Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Obstructive Stenosis of Major Coronary Vessels

ClinicalTrials.gov record

Registration

Registration
NCT02602600
Acronym
GAP
Study type
INTERVENTIONAL
Phase
PHASE4
Masking
NONE
Status
COMPLETED
Enrollment
33
Start
2015-11-19
Primary completion
2017-04-18
Lead sponsor
Eva Prescott
Conditions
Microvascular Angina
Interventions
DRUG:Liraglutide
Results posted
FALSE

Registered primary outcomes

  • Change from baseline in Coronary Flow Reserve [Assessed at baseline, week 4 and week 18]
  • Change from baseline in Angina Symptoms [Assessed at baseline, week 4 and week 18]

Linked records (7)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0024727Effect of liraglutide on body weight and microvascular function in non-diabetic overweight women with coronary microvascular dysfunction.
Suhrs HE, International journal of cardiology
2019Other trialPMID 30773266DOIcites ClinicalTrials.gov:NCT02602600; registry reference DERIVED:30773266
R0018665Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study.
Faber R, Cardiovascular diabetology
2015Randomized trialPMID 25896352DOIregistry reference RESULT:25896352
R0016018Cardiovascular actions of incretin-based therapies.
Ussher JR, Circulation research
2014Narrative reviewPMID 24855202DOIregistry reference RESULT:24855202
R0026296Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study.
Woo JS, Arteriosclerosis, thrombosis, and vascular biology
2013Randomized trialPMID 23868944DOIregistry reference RESULT:23868944
R0026946Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia.
Lønborg J, Circulation. Cardiovascular interventions
2012Randomized trialPMID 22496084DOIregistry reference RESULT:22496084
R0021038GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.
Noyan-Ashraf MH, Diabetes
2009PreclinicalPMID 19151200DOIregistry reference RESULT:19151200
R0027817Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
Ban K, Circulation
2008PreclinicalPMID 18427132DOIregistry reference RESULT:18427132